SJS Investment Consulting
MLYS icon

SJS Investment Consulting’s Mineralys Therapeutics MLYS Stock Holding History

SJS Investment Consulting’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$528 Buy
21
+9
+75% +$245 ﹤0.01% 2729
2026
Q2 		$324 Hold
12
– – ﹤0.01% 2379
2026
Q1 		$326 Buy
+12
New +$352 ﹤0.01% 1874

Other funds holding MLYS

Catalys Pacific
Catalys Pacific Tokyo, Japan $210M AUM 33.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Laurion Capital Management
Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Andera Partners
Andera Partners Paris $176M AUM 1.8% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

SJS Investment Consulting's MLYS Position: Q3 2026 in Review

SJS Investment Consulting increased its Mineralys Therapeutics (MLYS) stake by 75% in Q3 2026, buying an estimated $245 and bringing the position to 21 shares worth $528. The position accounts for ﹤0.01% of the portfolio, ranked #2729.

SJS Investment Consulting first reported a position in MLYS in Q1 2026 and has held it in 3 quarters since. 146 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

  • SJS Investment Consulting held 21 shares of Mineralys Therapeutics worth $528 as of Q3 2026.
  • SJS Investment Consulting bought 9 Mineralys Therapeutics shares in Q3 2026, an estimated $245.
  • Mineralys Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q3 2026, its #2729 holding.
  • SJS Investment Consulting first reported a position in Mineralys Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 146 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on SJS Investment Consulting's 13F filing for Q3 2026, filed 26 Oct 2026.